Breaking News Instant updates and real-time market news.

AEHR

Aehr Test Systems

$1.48

-0.07 (-4.52%)

, FC

Franklin Covey

$25.81

0.16 (0.62%)

18:56
04/04/19
04/04
18:56
04/04/19
18:56

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Aehr Test Systems (AEHR) up 22.8%... Franklin Covey (FC) up 6.3%. ALSO HIGHER: Century Communities (CCS) up 7.0% after its announced entry into S&P SmallCap 600 index... Boot Barn (BOOT) up 7.0% after its announced entry into S&P SmallCap 600 index... Triumph Group (TGI) up 6.0% after announcing it is exploring strategic alternatives for Aerospace Structures unit... Viacom (VIAB) up 1.7% after being upgraded to Outperform at RBC Capital. DOWN AFTER EARNINGS: Duluth Holdings (DLTH) down 18.7%. ALSO LOWER: Syros Pharma (SYRS) down 21.0% after equity offering... Merrimack (MACK) down 14.4% after halting development of MM-310... Acceleron (XLRN) down 4.0% after discontinued Phase 1 Molecule ACE-2494 program... Waitr Holdings (WTRH) down 3.6% after equity offering. Movers as of 18:45ET.

AEHR

Aehr Test Systems

$1.48

-0.07 (-4.52%)

FC

Franklin Covey

$25.81

0.16 (0.62%)

CCS

Century Communities

$24.52

1.01 (4.30%)

BOOT

Boot Barn

$29.60

0.195 (0.66%)

TGI

Triumph Group

$21.38

2.06 (10.66%)

VIAB

Viacom

$29.26

-0.1 (-0.34%)

DLTH

Duluth Holdings

$23.51

-0.15 (-0.63%)

SYRS

Syros Pharmaceuticals

$9.76

-0.02 (-0.20%)

MACK

Merrimack

$7.17

0.01 (0.14%)

XLRN

Acceleron

$46.24

-0.71 (-1.51%)

WTRH

Waitr Holdings

$12.43

-0.16 (-1.27%)

  • 04

    Apr

  • 04

    Apr

  • 04

    Apr

  • 07

    May

  • 16

    May

  • 17

    May

  • 23

    May

  • 05

    Jun

  • 05

    Apr

AEHR Aehr Test Systems
$1.48

-0.07 (-4.52%)

FC Franklin Covey
$25.81

0.16 (0.62%)

12/28/18
BRRR
12/28/18
NO CHANGE
BRRR
Barrington sees increase in revenue , EBITDA in 2019 for Franklin Covey
Barrington analyst Alexander Paris reiterated an Outperform rating and $30 price target on Franklin Covey shares. The analyst sees a significant increase in revenue and adjusted EBITDA for the company in FY19 and beyond, as "the large amounts of high-profit margin deferred revenue become recognized as revenue and income." Paris added that he expects Franklin Covey to achieve accelerated revenue growth, "increasing gross margins and significantly increasing flow-through to adjusted EBITDA and cash flow in FY19 as significant growth investments begin to subside."
04/06/18
ROTH
04/06/18
NO CHANGE
Target $34
ROTH
Buy
Franklin Covey price target raised to $34 from $26 at Roth Capital
Roth Capital analyst Jeff Martin raised his price target to $34 from $26 and reiterated his Buy rating following the company's Q2 earnings report. In a research note to investors, the analyst said the company's transition to a subscription-based model is making "significant" strides, with subscription and subscription-related revenue up 55% in the quarter to $20M, or 43% of revenue. Rising attach rates of add-on services, currently 40% and rising, combined with greater than 90% revenue retention should appeal to investors that favor subscription-based business models, the analyst said.
04/05/18
BRRR
04/05/18
NO CHANGE
BRRR
Franklin Covey price target raised to $35 from $32 at Barrington
Barrington analyst Alexander Paris Jr. reiterated his Outperform rating on Franklin Covey and raised his price target to $35 from $32 on the stock, after the company reported its Q2 earnings results, which had EBITDA that exceeded both the firm's and the consensus estimates. Going forward, Paris expects Franklin Covey to "achieve accelerated revenue growth, increasing gross margins and significantly increasing flow-through to adjusted EBITDA and cash flow, in FY18 and beyond."
01/10/19
BRRR
01/10/19
NO CHANGE
BRRR
Franklin Covey Q1 earnings 'above expectations,' says Barrington
Barrington analyst Alexander Paris Jr. reiterated an Outperform rating and $30 price target on Franklin Covey after the company reported Q1 earnings results that were "above expectations," including Q1 revenue of $53.8M. which was above the firm's $51M estimate. The analyst also noted that Franklin Covey reaffirmed its FY19 guidance, which sees adjusted EBITDA in the range of $18M-22M, compared to $11.9M in FY18.
CCS Century Communities
$24.52

1.01 (4.30%)

03/07/19
ZELM
03/07/19
UPGRADE
ZELM
Buy
Century Communities upgraded to Buy from Hold at Zelman
02/08/19
WEDB
02/08/19
DOWNGRADE
Target $24
WEDB
Neutral
Century Communities downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Jay McCanless downgraded Century Communities to Neutral from Outperform and lowered his price target to $24 from $26. In a research note to investors, McCanless says that while the negative y/y order growth in Century's newly acquired unit, Wade Jurney Homes, may prove short-lived as Century adjusts the strategy, he is concerned that demand for the WJ product has not been as robust as he expected especially given WJ's ultra-low price approach. In light of that weakness and the Q4 negative order growth for Century's legacy businesses excluding Texas, he is stepping to the sidelines.
02/08/19
WEDB
02/08/19
DOWNGRADE
WEDB
Neutral
Century Communities downgraded to Neutral from Outperform at Wedbush
02/04/19
SUSQ
02/04/19
NO CHANGE
SUSQ
Susquehanna makes case for Century Communities and Redfin to be acquired
Susquehanna analyst Jack Micenko laid out a case for why he thinks Pulte (PHM) should buy Century Communities (CCS) and why Amazon.com (AMZN) should buy Redfin (RDFN). The analyst feels Pulte is under-penetrated in the true entry-level segment of the market and Century could quickly fill the need in terms of both product type and geography. He believes Pulte could pay a roughly 40% premium to Century's current stock price and still see accretion from the deal. As for Amazon, he noted they have been more active around housing than many appreciate and he believes the data opportunity with Redfin is significant. He said Amazon could pay a roughly 60% premium to Redfin's current stock price. Micenko has a Neutral rating and $25 price target on Pulte while he does not have a rating on shares of Century Communities. Amazon is covered by analyst Shyam Patil, who has a Positive rating and $2,250 price target, and Micenko has a Positive rating and $19 price target on Redfin shares.
BOOT Boot Barn
$29.60

0.195 (0.66%)

03/14/19
SIDC
03/14/19
INITIATION
SIDC
Buy
Boot Barn initiated with a Buy at Sidoti
01/02/19
WELS
01/02/19
NO CHANGE
Target $19
WELS
Market Perform
Boot Barn price target lowered to $19 from $29 at Wells Fargo
Wells Fargo analyst Tom Nikic lowered his price target for Boot Barn to $19 from $29, while reiterating a Market Perform rating on the shares. In a research note titled "2019 Retail Outlook report," the analyst says he believes Holiday reads likely slowed post Black Friday, Multinational brands struggled relative to retailers the past several months as concerns around Europe weakness, China uncertainty, a slowdown in tourism and FX pressures are growing, e-commerce meaningfully underperformed Brick and Mortar retail in 2018 as inflated multiples have been hit hard in the face of a painful tech ''unwind'' and choppier fundamentals, 2019 is likely to be worse than 2018 for the space, and Leases are coming onto retailers' balance sheets in 2019, making for worse capital structure optics.
01/02/19
JEFF
01/02/19
NO CHANGE
JEFF
Buy Gap, sell L Brands are Jefferies' best Consumer ideas for 2019
In the Consumer space, Jefferies analyst Randal Konik says his best ideas for 2019 are buying Gap (GPS) and selling L Brands (LB). The analyst recommends using the late 2018 selloff as an opportunity to get long consumer names for 2019. His other top Buy ideas are American Eagle (AEO), Boot Barn (BOOT), Capri Holdings (CPRI), Five Below (FIVE), Foot Locker (FL), Fox Factory (FOXF), Acushnet Holdings (GOLF), Kohl's (KSS), Manchester United (MANU), Ollie's Bargain Outlet (OLLI), Tiffany (TIF), Urban Outfitters (URBN), Under Armour (UAA) and Yeti (YETI). On L Brands, Konik continues to believe Victoria's Secret "is broken," Pink "is a fad" that's sales will get cut in half, and Bath & Body Works is at a "cyclical peak with daunting compares ahead." On the flip side, the analyst thinks Gap will be one of the top S&P 500 stocks in 2019. He recommends "aggressively" buying the shares at current levels.
01/07/19
PIVT
01/07/19
UPGRADE
Target $24
PIVT
Buy
Boot Barn upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Mitch Kummetz upgraded Boot Barn to Buy while lowering his price target for the shares to $24 from $27. The analyst views the stock's risk/reward as favorable at current levels. While oil prices have fallen, oil and gas employment has not, Kummetz tells investors in a research note. He sees Boot Barn achieving, if not exceeding, the high end of its fiscal Q3 guidance.
TGI Triumph Group
$21.38

2.06 (10.66%)

02/11/19
BOFA
02/11/19
UPGRADE
BOFA
Buy
Triumph Group upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill analyst Ronald Epstein double upgraded Triumph Group to Buy from Underperform with a $35 price target. Epstein said current management is undoing the "cash drag" from previous management acquisitions of Vought Aircraft Industries and the Gulfstream wing programs. The analyst said there is a visible and achievable pat towards positive free cash flow by FY21 and sees the Aerostructures group as a potential upside for shareholders.
02/11/19
COWN
02/11/19
DOWNGRADE
COWN
Market Perform
Triumph Group downgraded to Market Perform from Outperform at Cowen
02/08/19
RHCO
02/08/19
NO CHANGE
Target $25
RHCO
Hold
Triumph Group price target raised to $25 from $16 at SunTrust
SunTrust analyst Michael Ciarmoli raised his price target on Triumph Group to $25 after its Q3 results, saying that while its revenue missed consensus, the organic growth of 7% was solid. The analyst also cites the company's better than expected free cash flows and affirmed FY19 outlook, but keeps his Hold rating on the stock given the remaining headwinds around its "G280, E-2, and 747" programs.
01/25/19
01/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Flir Systems (FLIR) upgraded to Outperform from Neutral at Baird with analyst Peter Arment saying defense contract wins that are providing good visibility and current valuation, which provides a good risk/reward. 2. McCormick (MKC) upgraded to Hold from Sell at Deutsche Bank and to Overweight from Equal Weight at Consumer Edge. 3. Rockwell Automation (ROK) upgraded to Buy from Reduce at HSBC with analyst Michael Hagmann saying he views the correction in shares as "overdone" and said Rockwell offers robust secular automation fundamentals, strong cash flow generation, and best-in-class ROIC, with potential for end market improvement in FY19. 4. Triumph Group (TGI) upgraded to Outperform from Market Perform at Cowen with analyst Cai von Rumohr citing its Global 7500 program as it will reduce the company's risk, bolster 2020 free cash flow, and shift its mix to profitable sectors. 5. Carnival (CCL) upgraded to Outperform from Neutral at Macquarie with analyst Paul Golding citing valuation and favorable exposure to oil prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VIAB Viacom
$29.26

-0.1 (-0.34%)

03/29/19
03/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) upgraded to Market Perform from Underperform at Raymond James with analyst David Long saying the retirement of CEO Tim Sloan removes a "headwind." 2. Viacom (VIA, VIAB) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould citing the company's loss of its biggest distributor AT&T (T) having been de-risked which, he believes, raises the likelihood of a Viacom merger with CBS (CBS). 3. F5 Networks (FFIV) upgraded to Neutral from Underweight at Piper Jaffray with analyst James Fish saying after underperforming the tech sector and the market over the last six months by ~20%, some of the main downside share catalysts have played out. 4. Mosaic (MOS) upgraded to Neutral from Underperform at Credit Suisse with analyst Chris Parkinson citing modest downside to Chinese cash operating costs, lower immediate-term ammonia and sulfur costs, evidence of near-term volume discipline, the emphasis on long-term cost reduction programs and balance sheet stability. 5. KeyCorp (KEY) upgraded to Neutral from Reduce at Nomura Instinet with analyst Bill Carcache saying he believes the shares are near a fair valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/01/19
BNCH
04/01/19
NO CHANGE
Target $18
BNCH
Buy
Chicken Soup may now be one of hottest small properties in media, says Benchmark
Benchmark analyst Daniel Kurnos said Chicken Soup for the Soul (CSSE) "shocked" by announcing a joint venture with Sony (SNE) and "may have just become one of the hottest small properties in the media landscape" in the process. Kurnos believes that the new Crackle Plus will top Pluto TV from a content, monthly average user and total registered user standpoint, noting that Pluto was just sold to Viacom (VIAB) for $340M. Following the JV announcement, the analyst raised his price target on Chicken Soup shares to $18 from $16 and keeps a Buy rating on the stock.
04/04/19
GUGG
04/04/19
DOWNGRADE
Target $72
GUGG
Neutral
Guggenheim downgrades Roku on increasing competition from Apple, Amazon
Guggenheim analyst Michael Morris downgraded Roku (ROKU) to Neutral from Buy and lowered his price target for the shares to $72 from $77. The stock closed yesterday down 3%, or $2.04, to $68.60. Morris this morning also upgraded Facebook (FB) to Buy from Neutral with a $200 price target. Apple's (AAPL) video product unveiled on March 25 represents an additional risk to Roku's active user base, the analyst tells investors in a research note. Further, Amazon's (AMZN) and Viacom's (VIAB) greater pushes into advertising video on demand are also increasing competition on Roku, Morris contends. He adds that Roku CFO Steve Louden's sale of 100,000 shares has also "shaken" his confidence in the stock. Nonetheless, the analyst's view of the "strong" secular streaming and targeted video advertising tailwinds that the company is positioned to benefit from is unchanged.
04/04/19
RBCM
04/04/19
UPGRADE
RBCM
Outperform
Viacom upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Steven Cahall upgraded Viacom to Outperform from Sector Perform.
DLTH Duluth Holdings
$23.51

-0.15 (-0.63%)

03/06/19
03/06/19
DOWNGRADE
Target $24

Neutral
Duluth Holdings cut to Neutral at DA Davidson on weather and competition factors
As previously reported, DA Davidson analyst John Morris downgraded Duluth Holdings to Neutral from Buy and lowered his price target to $24 from $30. The analyst sees the transition to Spring as challenging for the company on signs of more promotional activity from its competitors as well as the "unseasonably late winter". Morris also points to the 20% gain in Duluth Holdings stock from its late January lows and believes that a neutral stance is warranted until visibility on the upcoming season improves.
03/06/19
DADA
03/06/19
DOWNGRADE
DADA
Neutral
Duluth Holdings downgraded to Neutral from Buy at DA Davidson
01/24/19
01/24/19
UPGRADE
Target $30

Buy
Duluth Holdings upgraded to Buy at DA Davidson on valuation
As previously reported, DA Davidson analyst John Morris upgraded Duluth Holdings to Buy from Neutral with an unchanged $30 price target, saying the pullback in the stock price now "discounts investors' concerns about the rocky systems implementation along with the promotional Holiday season." The analyst adds that the more favorable valuation on the stock is now "enough to overcome the lack of clarity" on the refinement to Duluth's systems installations. Morris further cites his expectations for Duluth to generate a "solid top-line growth in the high teens in the year ahead bolstered by continued store expansion opportunity along with efficiency benefits from the new systems upgrades beginning to pay off next year".
01/24/19
DADA
01/24/19
UPGRADE
DADA
Buy
Duluth Holdings upgraded to Buy from Neutral at DA Davidson
SYRS Syros Pharmaceuticals
$9.76

-0.02 (-0.20%)

11/16/18
PIPR
11/16/18
NO CHANGE
Target $28
PIPR
Overweight
Syros Phase I dose escalation data 'encouraging,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff found the Phase I dose escalation data presented by Syros Pharmaceuticals for its CDK7 inhibitor SY-1365 "encouraging." Intravenous SY-1365 was safe and well tolerated with manageable adverse events, Tenthoff tells investors in a research note. The analyst points out that one relapsed ovarian cancer patient achieved partial response with six additional patients with stable disease, bringing the disease control rate to 37% in seven of 19 evaluable patients. He reiterates an Overweight rating on Syros with a $28 price target.
02/14/19
OPCO
02/14/19
INITIATION
Target $13
OPCO
Outperform
Syros Pharmaceuticals assumed with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach assumed coverage of Syros Pharmaceuticals with an Outperform rating and a $13 price target. The analyst believes the company's lead program, SY-1425, has demonstrated compelling clinical proof-of-concept in a biomarker-defined population of acute myeloid leukemia patients and has an opportunity for approval in multiple therapeutic settings. However, recent changes in the AML competitive landscape, such as the approval of venetoclax, could limit uptake and prolong development timelines relative to previous estimates, he contends. Nonetheless, Breidenbach sees SY-1425 + azacitidine as a promising combination therapy in AML and expects the company to announce updated development plans in early 2019.
03/08/19
JMPS
03/08/19
INITIATION
Target $18
JMPS
Outperform
Syros Pharmaceuticals initiated with an Outperform at JMP Securities
JMP Securities transferred coverage of Syros Pharmaceuticals to analyst Jason Butler, who established an Outperform rating and $18 price target on the stock. He believes the company's recently updated clinical development strategies can provide faster paths to market and maximize commercial potential for SY-1425 and SY-1365, Butler tells investors.
03/08/19
03/08/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tilray (TLRY) initiated with an Underperform at Jefferies. 2. BB&T (BBT) initiated with a Buy at Odeon Capital. 3. Syros Pharmaceuticals (SYRS) initiated with an Outperform at JMP Securities. 4. W&T Offshore (WTI) initiated with a Buy at Stifel. 5. Ichor Holdings (ICHR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MACK Merrimack
$7.17

0.01 (0.14%)

06/25/18
JPMS
06/25/18
DOWNGRADE
JPMS
Underweight
Merrimack downgraded to Underweight from Neutral at JPMorgan
XLRN Acceleron
$46.24

-0.71 (-1.51%)

02/26/19
02/26/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Acceleron (XLRN) initiated with an Outperform at Cowen. 2. Target (TGT) assumed with a Neutral at Citi. 3. Capri Holdings (CPRI) reinstated with an Overweight. 4. Starwood Property (STWD) initiated with a Buy at BTIG. 5. Essential Properties Realty Trust (EPRT) initiated with a Market Perform at Raymond James. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/19
PIPR
03/06/19
NO CHANGE
PIPR
Departure of Gottlieb brings some biopharma uncertainty, says Piper Jaffray
Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.
02/26/19
HCWC
02/26/19
NO CHANGE
Target $72
HCWC
Buy
H.C. Wainwright keeps Buy rating on Acceleron after updated luspatercept timing
After Acceleron's (XLRN) partner, Celgene (CELG), announced updated timing for the anticipated submission of a Biologics License Application with the U.S. FDA for luspatercept, H.C. Wainwright analyst Edward White noted that the BLA is now seen being submitted in April 2019, versus prior guidance for the first half of 2019. He expects the drug to be launched in early 2020 and his expectations remain at $32.5M in 2020 sales for beta-thalassemia and $131.3M in 2020 sales for myelodysplastic syndromes, or MDS. White keeps a Buy rating and $72 price target on Acceleron shares.
02/25/19
COWN
02/25/19
INITIATION
Target $78
COWN
Outperform
Cowen starts Acceleron with Outperform rating, calls it top mid-cap pick
Cowen analyst Yaron Werber initiated Acceleron with an Outperform rating and $78 price target, stating that he anticipates filing in H1:19 and approval in H1:20 for luspatercept for transfusion-dependent beta-thalassemia and that his consultants expect "rapid uptake." He also has "high conviction" that the ongoing phase 3 COMMANDS study in first-line myelodysplastic syndromes in H1:21 and the phase 2 BEYOND study for non-transfusion dependent beta-thal will be positive, said Werber, who called Acceleron his top mid-cap pick.
WTRH Waitr Holdings
$12.43

-0.16 (-1.27%)

12/13/18
BNCH
12/13/18
NO CHANGE
Target $18
BNCH
Buy
Waitr Holdings price target raised to $18 on Bite Squad deal at Benchmark
Benchmark analyst Daniel Kurnos said Waitr Holdings' acquisition of Bite Squad will effectively double Waitr's size and market footprint and he sees significant value creation from the deal. Kurnos, who estimates the combined entity could generate over $250M in revenue in 2019 and over $410M in 2020, keeps a Buy rating on Waitr shares and raised his price target on the stock to $18 from $16.
03/14/19
JEFF
03/14/19
INITIATION
Target $18
JEFF
Buy
Jefferies starts Waitr Holdings at Buy, adds to top small cap pick list
Jefferies analyst Brent Thill initiated coverage of Waitr Holdings with a Buy rating and $18 price target. The company offers a unique opportunity to play the "highly underpenetrated" online food delivery space at a "discounted" valuation, Thill tells investors in a research note. He says Waitr trades at a 40% discount to global food delivery comps and a 17% discount to marketplace peers. As such, the analyst sees a current shares levels as a "compelling" entry point. Thill adds Waitr Holdings to his firm's top small cap pick list.
03/14/19
JEFF
03/14/19
INITIATION
Target $18
JEFF
Buy
Waitr Holdings initiated with a Buy at Jefferies
Jefferies analyst Brent Thill started Waitr Holdings with a Buy rating and $18 price target.
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).

TODAY'S FREE FLY STORIES

CNSL

Consolidated Communications

$6.03

-2.86 (-32.17%)

14:29
04/25/19
04/25
14:29
04/25/19
14:29
Downgrade
Consolidated Communications rating change  »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

BB

BlackBerry

$9.11

0.205 (2.30%)

14:25
04/25/19
04/25
14:25
04/25/19
14:25
Options
BlackBerry call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 16

    May

  • 17

    May

TSLA

Tesla

$247.99

-10.71 (-4.14%)

14:24
04/25/19
04/25
14:24
04/25/19
14:24
Hot Stocks
Tesla to delay $1,000 full self-driving price hike until May 10, CEO says »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUMA

Yuma Energy

$0.47

0.1991 (72.40%)

14:22
04/25/19
04/25
14:22
04/25/19
14:22
Hot Stocks
Breaking Hot Stocks news story on Yuma Energy »

Yuma Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEC

WEC Energy

$78.05

1.09 (1.42%)

14:21
04/25/19
04/25
14:21
04/25/19
14:21
Earnings
WEC Energy sees Q2 EPS 70c-72c, consensus 74c »

Says guidance assumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 21

    May

MDP

Meredith

$58.39

0.04 (0.07%)

14:19
04/25/19
04/25
14:19
04/25/19
14:19
Periodicals
Breaking Periodicals news story on Meredith »

Authentic Brands in talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 09

    May

  • 13

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
04/25/19
04/25
14:17
04/25/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNSL

Consolidated Communications

$6.09

-2.805 (-31.55%)

14:16
04/25/19
04/25
14:16
04/25/19
14:16
Downgrade
Consolidated Communications rating change at Raymond James »

Consolidated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 29

    Apr

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
04/25/19
04/25
14:16
04/25/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEC

WEC Energy

$77.97

1.01 (1.31%)

14:12
04/25/19
04/25
14:12
04/25/19
14:12
Earnings
WEC Energy sees FY19 EPS at high end of $3.48-$3.52 range, consensus $3.51 »

Says on track to add…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 21

    May

F

Ford

$9.41

-0.17 (-1.77%)

, GM

General Motors

$39.12

-0.61 (-1.54%)

14:10
04/25/19
04/25
14:10
04/25/19
14:10
Earnings
Fly Intel: What to watch in auto sector earnings reports »

Ford (F) is scheduled to…

F

Ford

$9.41

-0.17 (-1.77%)

GM

General Motors

$39.12

-0.61 (-1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 30

    Apr

  • 01

    May

  • 03

    May

  • 09

    May

  • 05

    Jun

  • 24

    Jul

  • 23

    Oct

CPRI

Capri Holdings

$44.85

-1.26 (-2.73%)

14:05
04/25/19
04/25
14:05
04/25/19
14:05
Options
Capri Holdings call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
04/25/19
04/25
14:00
04/25/19
14:00
General news
Treasury Action: the market has eroded slightly »

Treasury Action: the…

CLB

Core Laboratories

$66.31

-6.595 (-9.05%)

13:51
04/25/19
04/25
13:51
04/25/19
13:51
Recommendations
Core Laboratories analyst commentary at Stifel »

Core Laboratories…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 01

    May

AVP

Avon Products

$3.13

0.175 (5.92%)

13:49
04/25/19
04/25
13:49
04/25/19
13:49
Periodicals
Natura said to be in advanced talks to acquire Avon, Valor Economico says »

Natura is in advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 16

    May

DLPH

Delphi Technologies

$22.60

-2 (-8.13%)

13:45
04/25/19
04/25
13:45
04/25/19
13:45
Options
Delphi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ADTN

Adtran

$17.39

-0.38 (-2.14%)

13:40
04/25/19
04/25
13:40
04/25/19
13:40
Earnings
Adtran VP Roger Shannon sold over $100K in company shares »

Adtran VP Roger Shannon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 08

    May

AVYA

Avaya

$20.22

0.895 (4.63%)

13:34
04/25/19
04/25
13:34
04/25/19
13:34
Periodicals
Mitel offering to combine with Avaya in stock deal worth over $2B, WSJ says »

Avaya is in talks to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

TECK.B

Teck Corp.

$0.00

(0.00%)

13:34
04/25/19
04/25
13:34
04/25/19
13:34
Conference/Events
Teck Corp. management to meet with B.Riley FBR »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

CWT

California Water Service

$49.43

-0.57 (-1.14%)

13:32
04/25/19
04/25
13:32
04/25/19
13:32
Upgrade
California Water Service rating change at Wells Fargo »

California Water Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

BHC

Bausch Health

$23.18

0.16 (0.70%)

13:30
04/25/19
04/25
13:30
04/25/19
13:30
Hot Stocks
Breaking Hot Stocks news story on Bausch Health »

Bausch Health trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 06

    May

  • 06

    May

AVYA

Avaya

$20.20

0.875 (4.53%)

13:28
04/25/19
04/25
13:28
04/25/19
13:28
Periodicals
Mitel offers to combine with Avaya in stock deal, WSJ says »

Mitel's bid values…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

CLVS

Clovis

$19.43

-0.4 (-2.02%)

13:25
04/25/19
04/25
13:25
04/25/19
13:25
Options
Clovis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 31

    May

AGN

Allergan

$140.66

0.98 (0.70%)

, TEVA

Teva

$15.07

0.065 (0.43%)

13:25
04/25/19
04/25
13:25
04/25/19
13:25
Conference/Events
Piper Jaffray specialty pharma analysts to hold analyst/industry conference call »

Specialty Pharmaceuticals…

AGN

Allergan

$140.66

0.98 (0.70%)

TEVA

Teva

$15.07

0.065 (0.43%)

ALDR

Alder Biopharmaceuticals

$13.95

0.29 (2.12%)

AMGN

Amgen

$179.82

1.56 (0.88%)

BHVN

Biohaven Pharmaceutical

$62.30

-0.855 (-1.35%)

LLY

Eli Lilly

$117.99

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 28

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

  • 21

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

ZM

Zoom Video

$64.49

1.175 (1.86%)

13:21
04/25/19
04/25
13:21
04/25/19
13:21
Hot Stocks
Zoom, Slack announce new partnership »

Zoom and Slack have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.